Navigation Links
Ambit Biosciences Announces Third Quarter 2013 Operating Results
Date:11/7/2013

se of this study is to assess the efficacy and safety of lower doses of quizartinib in the treatment of patients 18-years or older with relapsed/refractory FLT3 ITD positive AML to further improve the benefit:risk assessment of quizartinib. The data will be presented by Dr. Jorge Cortes at 3:00 pm CT on Monday, December 9, in the La Nouvelle Ballroom C.

Quizartinib Can Be Safely Combined With Conventional Chemotherapy In Older Patients With Newly Diagnosed Acute Myeloid Leukemia: Experience From The AML Pilot Trial:  This is the first presentation of quizartinib use in combination with chemotherapy in newly diagnosed older AML patients, testing the feasibility and dose which could be given sequentially following conventional chemotherapy in patients over the age of 60 years.  The data will be presented by Dr. Alan Burnett at 5:15 pm CT on Monday, December 9, in the La Nouvelle Ballroom C.

Results of Phase 1 Study of Quizartinib In Combination with Induction and Consolidation Chemotherapy in Younger Patients with Newly Diagnosed Acute Myeloid Leukemia:  This dose escalation study is the first to report data on quizartinib in combination with standard induction and consolidation chemotherapy in patients between the ages of 18 to 60-years with newly diagnosed AML, regardless of FLT3 status. The data will be presented by Dr. Jessica Altman at 5:30 pm CT on Monday, December 9, in the La Nouvelle Ballroom C.

A Phase I Study of Quizartinib in Combination with Cytarabine and Etoposide in Relapsed/Refractory Childhood ALL and AML:  A Therapeutic Advances in Childhood Leukemia & Lymphoma Study:  This was the first clinical trial using quizartinib in children between the ages of 1 month and 21-years with relapsed/refractory AML or MLL-rearranged ALL.  The data will be presented by Dr. Todd Coope
'/>"/>

SOURCE Ambit Biosciences
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Ambit Announces Participation At 12th Annual BIO Investor Forum
2. Ambit Announces Participation At The BioCentury NewsMakers in the Biotech Industry Conference
3. Ambit Announces Presentation of Results from Phase 2 ACE Study of Quizartinib in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) at the Annual Meeting of the American Society of Clinical Oncology
4. Ambit Biosciences Files Registration Statement for Proposed Initial Public Offering
5. APAC Stem Cell Research & Therapy Market a “Growth Engine” for Region’s Scientific Ambitions Says A New Market Research Report at ReportsnReports.com
6. Astellas and Ambit Announce Data Presentations Highlighting Quizartinib at the American Society of Hematology 54th Annual Meeting
7. Ambit Biosciences to Present at Two Upcoming Investor Conferences
8. Ambit and Astellas Announce Results From Multiple Quizartinib Presentations at the 53rd Annual Meeting of the American Hematology Society
9. Ambit Biosciences Names Michael A. Martino President and Chief Executive Officer
10. Pressure BioSciences, Inc. Reports Third Quarter 2013 Financial Results and Provides Business Update
11. Juneau Biosciences Names Dr. Dinesh Patel to Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... According to a new market report published by ... was valued at USD 3,754.6 million in 2012 and is ... a CAGR of 5.9% from 2013 to 2019. , Nearly ... afflicted by bone and joint disorders, and this number is ... and will continue to increase the demand for orthobiologics. Other ...
(Date:8/29/2014)... PA (PRWEB) August 29, 2014 Pittcon ... Hub MacDonald, and colleague Koichiro Matsuda, Horiba Scientific, have ... on September 5, 2014. JASIS , Asia’s largest ... 3-5, 2014, in Makuhari Messe, Japan. , The ... Tools for Bioanalysis from Single Molecules to Single Cells” ...
(Date:8/29/2014)... /PRNewswire/ - iCo Therapeutics ("iCo" or "the Company") ... for the six months ended June 30, 2014. ... dollars and presented under International Financial Reporting Standards ... , Announced top-line results related to the ... subjects enrolled in the Phase 2 iDEAL Study ...
(Date:8/29/2014)... Hills, NY (PRWEB) August 29, 2014 ... Burnt Hills Veterinary Hospital are seeking candidates to participate ... dogs with osteoarthritis. The ultimate goal of this ... donor stem cells into one or two arthritically affected ... treated joints. , Candidates for the current investigational ...
Breaking Biology Technology:Global Orthobiologics Market to Reach $5,519.9 Million by 2019: Transparency Market Research 2Global Orthobiologics Market to Reach $5,519.9 Million by 2019: Transparency Market Research 3Fifth Annual U.S. Symposium at JASIS Organized by Pittcon’s Program Chairman Hub MacDonald 2iCo Therapeutics Announces Second Quarter 2014 Financial Results 2iCo Therapeutics Announces Second Quarter 2014 Financial Results 3iCo Therapeutics Announces Second Quarter 2014 Financial Results 4Burnt Hills Veterinary Hospital Seeks Candidates for an Investigational Study of Stem Cells for Dogs with Arthritis 2
... Mass., Oct. 20 Genstruct Inc., a systems,biology ... to better understand large-scale biology, announced today that,it ... of Engineering. In his,new role, Dr. Ray will ... Genstruct technology platform, customer platforms and the company,s,IT ...
... Senomyx, Inc.,(Nasdaq: SNMX ) will release its third ... the opening of the U.S. financial,markets. The Company will ... that will provide a business update and a review ... 11:00 a.m. Eastern Time (8:00 a.m.,Pacific Time)., To ...
... as President , ... San Diego/Phoenix (PRWEB) October ... based on the products of newborn dermal fibroblasts, today announced the ... growing medical aesthetic industries based on Histogen,s core technology. , , ...
Cached Biology Technology:Genstruct Expands Team with New VP of Engineering 2Genstruct Expands Team with New VP of Engineering 3SENOMYX, INC. THIRD QUARTER 2008 EARNINGS CONFERENCE CALL SCHEDULED FOR NOVEMBER 6, 2008 2Histogen Aesthetics is Created to Address Growing Medical Aesthetics Market 2Histogen Aesthetics is Created to Address Growing Medical Aesthetics Market 3Histogen Aesthetics is Created to Address Growing Medical Aesthetics Market 4
(Date:8/28/2014)... (LMU) in Munich have assigned a number of ... arthropods. These animals lived in shallow marine habitats ... found in Jurassic strata. , Before they ... habitat and were fossilized some 435 million years ... the Silurian seas although they were not ...
(Date:8/27/2014)... single fungal cell or bacterial colony exerts on a plant ... role in setting up some of the most fundamental symbiotic ... much of a stretch to say that plants may have ... the touch of beneficial fungi, according to a new study ... University of Wisconsin-Madison. , "Many people have studied how ...
(Date:8/27/2014)... short-faced bears, giant ground sloths, saber-toothed cats and American ... ago at the end of the Pleistocene period. The ... by scientists who, until recently, could only speculate as ... Santa Barbara,s James Kennett, professor emeritus in the Department ... Earth played a major role in the extinction. Their ...
Breaking Biology News(10 mins):Paleontology: Oldest representative of a weird arthropod group 2A touching story: The ancient conversation between plants, fungi and bacteria 2A touching story: The ancient conversation between plants, fungi and bacteria 3Nanodiamonds are forever 2Nanodiamonds are forever 3
... the process by which a biological cell divides into ... on that evolution has conserved it across the eons ... the U.S. Department of Energy's Lawrence Berkeley National Laboratory ... that the core machinery for initiating DNA replication is ...
... method to estimate population, have found that there may be ... thought. , The giant panda is one of the world's ... a restricted mountainous region in China with an unusual dietary ... nature has shielded important knowledge needed to save it from ...
... healthy? To answer this, Sea Grant biologists are cracking ... claim: the more parasites, the healthier the marsh. , ... about infectious disease and human health (malaria, for example, ... are investigating are not just any kind of parasite. ...
Cached Biology News:Molecular DNA switch found to be the same for all life 2Molecular DNA switch found to be the same for all life 3Molecular DNA switch found to be the same for all life 4Molecular DNA switch found to be the same for all life 5Brighter future for giant panda? 2Even a little cooling helps after cardiac arrest 2Even a little cooling helps after cardiac arrest 3
... formulated for non-denaturing polyacrylamide and agarose gel ... solution contains a bromophenol blue tracking dye ... sample loading. EDTA has been included to ... SDS has been added to help dissociate ...
... Antibody Description: ... antibody. Detects 70 kDa YAP from ... and immunohistochemistry. ... Storage: -20C ...
...
... M-PER Mammalian Protein Extraction ... cell lysis solution that means ... and no sonication! With M-PER ... just five minutes at room ...
Biology Products: